Data / Research funding / California / Gigamune, Inc.
Gigamune, Inc.: 7 NIH awards ($2.5M), fiscal years 2021 to 2026
Gigamune, Inc. in San Francisco, CA is funded under 7 NIH awards ($2.5M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- KD8GTLK3VV93
- State
- California
Awards
7 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Engineered TCR-T Cell Therapy Targeting Driver Mutations in NSCLC | NIH | National Cancer Institute | 2021 | $400,000 | May 1, 2021 | April 30, 2022 | SPINDLER, MATTHEW JAMES | reporter.nih.gov |
| Engineered TCR-T Cell Therapies Targeting Shared Tumor Associated Antigens | NIH | National Cancer Institute | 2021 | $400,000 | August 1, 2021 | July 31, 2023 | SPINDLER, MATTHEW JAMES | reporter.nih.gov |
| A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma | NIH | National Cancer Institute | 2025 | $400,000 | September 15, 2025 | August 31, 2026 | JOHNSON, DAVID SCOTT | reporter.nih.gov |
| Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $355,000 | May 3, 2023 | June 30, 2023 | SPINDLER, MATTHEW JAMES | reporter.nih.gov |
| In vivo Gene Delivery to Regulatory T Cells to Drastically Reduce the Cost of Regulatory T Cell Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $300,000 | April 19, 2023 | March 31, 2025 | JOHNSON, DAVID SCOTT | reporter.nih.gov |
| In vivo Sickle Cell Disease Gene Therapy Using a Novel Virus Like Particle | NIH | National Heart, Lung, and Blood Institute | 2024 | $300,000 | September 10, 2024 | September 9, 2025 | JOHNSON, DAVID SCOTT | reporter.nih.gov |
| Delivery of Full Length Dystrophin to Muscle Cells for DMD Gene Therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $295,294 | September 1, 2023 | August 31, 2025 | JOHNSON, DAVID SCOTT | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 1 | $400,000 | 0 | $0 |
| 2024 | 1 | $300,000 | 0 | $0 |
| 2023 | 3 | $650,294 | 0 | $0 |
| 2022 | 1 | $300,000 | 0 | $0 |
| 2021 | 2 | $800,000 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Topics of its NIH awards
- Biotechnology
- Gene Therapy
- Genetics
- Bioengineering
- Cancer
- Immunotherapy
- Rare Diseases
- Pediatric
- Orphan Drug
- Hematology
- Human Genome
- Lung
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.